Success Metrics

Clinical Success Rate
87.5%

Based on 7 completed trials

Completion Rate
88%(7/8)
Active Trials
0(0%)
Results Posted
43%(3 trials)
Terminated
1(13%)

Phase Distribution

Ph phase_2
3
38%
Ph early_phase_1
1
13%
Ph phase_1
4
50%

Phase Distribution

5

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution8 total trials
Early Phase 1First-in-human
1(12.5%)
Phase 1Safety & dosage
4(50.0%)
Phase 2Efficacy & side effects
3(37.5%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

87.5%

7 of 8 finished

Non-Completion Rate

12.5%

1 ended early

Currently Active

0

trials recruiting

Total Trials

8

all time

Status Distribution
Completed(7)
Terminated(1)

Detailed Status

Completed7
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
0
Success Rate
87.5%
Most Advanced
Phase 2

Trials by Phase

Early Phase 11 (12.5%)
Phase 14 (50.0%)
Phase 23 (37.5%)

Trials by Status

terminated113%
completed788%

Recent Activity

0 active trials
Showing 5 of 8
completedearly_phase_1

A Study Exploring the Use of Vaccine and Antigen Challenges for Immune Monitoring in Healthy Participants

NCT03953196
completedphase_1

A Study Validating the Use of Candin as a Challenge Agent in Healthy Participants - Intervention Specific Appendix 2

NCT04611971
completedphase_1

A Study Validating the Use of Candin as a Challenge Agent in Healthy Participants - Intervention Specific Appendix 1

NCT04589026
completedphase_1

A Study Validating the Use of Candin as a Challenge Agent in Healthy Participants - Intervention Specific Appendix 4

NCT05522517
terminatedphase_1

Assessment of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 Peptide Antigens

NCT05216510
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT03953196Early Phase 1

A Study Exploring the Use of Vaccine and Antigen Challenges for Immune Monitoring in Healthy Participants

Completed
NCT04611971Phase 1

A Study Validating the Use of Candin as a Challenge Agent in Healthy Participants - Intervention Specific Appendix 2

Completed
NCT04589026Phase 1

A Study Validating the Use of Candin as a Challenge Agent in Healthy Participants - Intervention Specific Appendix 1

Completed
NCT05522517Phase 1

A Study Validating the Use of Candin as a Challenge Agent in Healthy Participants - Intervention Specific Appendix 4

Completed
NCT05216510Phase 1

Assessment of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 Peptide Antigens

Terminated
NCT02481414Phase 2

A Clinical Trial of PepCan to Two Therapy Arms for Treating Cervical High-Grade Squamous Intraepithelial Lesions

Completed
NCT02393417Phase 2

Safety and Efficacy of Varying Regimens of CANDIN for Treatment of Common Warts (Verruca Vulgaris)

Completed
NCT01650389Phase 2

Safety and Immunogenicity of MVA85A Prime and Bacille Calmette-Guerin Boost Vaccination

Completed

All 8 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
8